Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer

Figure 1 Serum tumor marker levels in the two colorectal cancer treatment groups. The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen. A: Pre- and posttreatment carcinoembryonic antigen levels in the two groups. B: Pre- and posttreatment carbohydrate antigens (CA)19-9 levels in the two groups; C: Pre- and posttreatment CA242 levels in the two groups. ^aP < 0.05 compared to pre-treatment levels; ^bP < 0.01 compared to pre-treatment levels. CEA: Carcinoembryonic antigens; CA: Carbohydrate antigens.